Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Paller, A. S., Siegfried, E. C., Cork, M. J., Wollenberg, A., Arkwright, P. D., Gonzalez, M. E., Lockshin, B., Chen, Z., Bansal, A., Levit, N. A. & Prescilla, R., Jan 2023, In: Pediatric Drugs.25, 1, p. 67-7711 p.
Research output: Contribution to journal › Article › peer-review
Paller, A. S. (Creator), Siegfried, E. C. (Creator), Cork, M. J. (Creator), Wollenberg, A. (Creator), Arkwright, P. D. (Contributor), Gonzalez, M. E. (Creator), Lockshin, B. (Creator), Chen, Z. (Creator), Bansal, A. (Creator), Levit, N. A. (Creator), Prescilla, R. (Creator) (2023). Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Adis Journals. 10.6084/m9.figshare.21684995.v2